Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The investigators propose to investigate if using a combination of medications that may
improve cholesterol give additional benefit to that gained from the statin medication,
Lipitor. It is recommended that patients who meet certain criteria for risk of heart disease
take a statin medication to improve cholesterol and hopefully reduce risk of heart disease.
The combination therapy will include Lipitor, Niaspan, and investigational medication (known
as ABT335) in a class of drugs called fibrates. We are looking to see if and how these three
medications together might improve risk factors for atherosclerosis and influence HDL
cholesterol. The study will also look at the safety and any side effects that might be
associated with this combination of medications.